University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 19 of 35
Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)
NCT03609814
Mailed FIT Outreach to Improve Colon Cancer Screening in the Safety-net System
NCT02613260
Adductor Canal Block Versus Femoral Block on Pain and Quadriceps Strength
NCT05190120
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
NCT02966145
Effect of a Patient-Centered Decision App on TOLAC
NCT02646423
AABM to Decrease Problem Drinking and Impulsivity in Veterans With AUD: A Pilot Study
NCT02600832
Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis
NCT02294981
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
NCT02508636
Neck Drains for SLNDs
NCT03113526
Use of Pedometers to Measure and Increase Walking Among Patients With ESRD
NCT02623348
Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear
NCT02410954
Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression
NCT02440815
Cross-linking for Corneal Ulcers Treatment Trial
NCT02570321
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
NCT02384239
Intranasal Oxytocin and Enhancement of Team Cohesion
NCT02302430
Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension
NCT02265965
Online Peer Influence on IUD Behaviors and Attitudes
NCT02279043
Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder Functional Outcomes
NCT02588027
Feeding America Intervention Trial for Health--Diabetes Mellitus
NCT02569060
Transcorporal Versus Standard Artificial Urinary Sphincter Placement
NCT02591381
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
NCT03609827
Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program
NCT02103348
Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons
NCT02059408
Uniformity of Oral Contrast Material in the Bowel
NCT02542046
Immune Monitoring in Sensitized Patients at Risk of Rejection
NCT03794817
Trial of pIL-12/MK-3475 in Metastatic Melanoma
NCT02493361
Development of a Couple-Based Mobile Health Intervention for Enhancing HIV Care Engagement Outcomes (N'Gage)
NCT03100643
The END Perioperative Smoking Pilot Study
NCT02482233
Changes in Sugar-sweetened Beverage Intake and Metabolic Health: Improving Metabolic Profile Very Effortlessly
NCT02585336
Clinical Pharmacology of Electronic Cigarettes
NCT02470754
The Healthy Heart Study
NCT02105246
Anesthetic Depth and Postoperative Delirium Trial - 2
NCT01983384
Cardiac MRI in Pulmonary Hypertension
NCT02485977
Pilot of Letrozole for Uterine Myomas
NCT02470741
Cromolyn Detection of Silent Aspiration
NCT01841307
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
NCT02458235
Web-based Lifestyle Trial Among Men With Prostate Cancer: Prostate 8
NCT02470936
Fecal Microbiota Transplant for Inflammatory Bowel Disease
NCT02460705
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02187133
Reversing Therapy Resistance With Epigenetic-Immune Modification
NCT02395627
A Family-Focused Intervention for Asian American Male Smokers
NCT02307734
Pay For Success: Permanent Supportive Housing for the Chronically Homeless
NCT02440360
Young Plasma Transfusions for Progressive Supranuclear Palsy
NCT02460731
San Francisco Health Plan Care Support Trial
NCT02463838
Yoga During Chemotherapy Study
NCT02442635
Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers
NCT02423720
11C- and 18F-Choline PET/MR Imaging for Prostate Cancer
NCT02397408
FACE-PC: Family-Centered Care for Older Adults With Depression and Chronic Medical Conditions in Primary Care
NCT03094871
iStart Smart for Teens for Healthy Weight Management
NCT01693250
Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)
NCT02330419
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.